Ruxolitinib and Azacitidine for Myelofibrosis
NEJM Journal Watch（2018）
摘要
The JAK1 and JAK2 inhibitor ruxolitinib has emerged as an effective treatment for patients with myelofibrosis (MF; NEJM JW Oncol Hematol Oct 2012 and
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要